Loading…
For intermediate-risk patients: clarifying. With family history at low baseline: arguably the most cost-effective screen.
CAC reclassifies cardiovascular risk; cost and radiation are low for the information gain.
Our read is Partially Supported. The core mechanism holds and the direction is right, but the popular framing tends to overrun what the trials actually show. With a developing evidence base (74/100) and a working majority (78% consensus), getting a CAC score at 40+ is reasonable for the right person at $0/month — just calibrate the expectation to the data, not the marketing.
Pulled the public claims about getting a CAC score at 40+ from proponents on file (a tracked voice) and weighed them against the more cautious voices in the field, then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Downside risk on getting a CAC score at 40+ is low at sensible doses, but low risk is not no risk: individual response varies, and a low-risk intervention is still only worth it if the benefit is real.
A large, long-duration RCT in a general population that either confirms a hard-outcome benefit or shows the effect washes out once it is properly controlled.
Benefits hold across the populations where it's been tested.
The intervention improves the primary outcome at standard doses in healthy adults.
Mechanistic and trial evidence converge on a real, replicable effect.
Benefits hold across the populations where it's been tested.
The effect size is large enough to matter clinically, not just statistically.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.
Animal-model results don't translate to the human protocol being recommended.
Animal-model results don't translate to the human protocol being recommended.
Most of the support comes from short or small studies.